What ProMed Pharma does

ProMed Pharma is a privately held contract development and manufacturing organization (CDMO) headquartered in Maple Grove, Minnesota, established in 2006 as a sister entity to ProMed Molded Products (which has 30+ years of medical device molding history). The company is purpose-built around polymer-based long-acting injectable and implantable drug delivery dosage forms, serving both established pharmaceutical companies and early-stage biotechs, alongside medical device companies developing drug-device combination products. Its therapeutic reach spans ophthalmology, women's health, oncology, drug-device combination products, and macromolecule delivery, and it runs development programs with the Bill & Melinda Gates Foundation in the global health segment.

The technical platform is built on silicone, thermoplastic (EVA), and biodegradable (PLGA) polymer excipients, delivered through four core manufacturing capabilities: polymer-based controlled release, injection molding with API mixing, microextrusion (implants below 100 microns, coextrusion for near zero-order release), and proprietary Faros microsphere technology with tightly controlled 2–50 µm particle sizes and engineered release profiles from approximately 3 to over 180 days. Supporting capabilities include custom isolators for HPAPI handling (OEB Class 4+), DEA Schedule III registration (May 2025) for controlled substances, cGMP manufacturing compliant with 21 CFR 210/211 and 820, device assembly/packaging/sterilization, and an analytical and stability testing footprint exceeding 2,000 sq ft with HPLC, UPLC, GPC, FTIR, DSC, rheometry, viscometry, USP apparatus, and laser microscopy instrumentation.

ProMed operates a B2B enterprise field sales model with quote-based, project-specific pricing, dedicated project managers, and multi-year contract cadences. Revenue flows from development fees and manufacturing services spanning early-stage feasibility (10–20 projects per year, 4–8 week turnaround), tech transfer and scale-up, cGMP manufacturing, and analytical services. Physical footprint comprises Maple Grove HQ and a 20,000 sq ft development facility (established 2021), Plymouth manufacturing including ISO Class 7 suites (15,000+ sq ft), ProMed Development Center in Plymouth, the ProMed Caribe facility in Dorado, Puerto Rico, and most recently a 28,000 sq ft Niagara Lane plant acquired from Bora Pharmaceuticals in August 2025 that is being built out as a four-suite pharma condo model. Two of the four planned Niagara Lane suites were committed by undisclosed pharma partners in January and June 2026, and the SpineThera microsphere manufacturing assets were absorbed in April 2024.

Name

ProMed Pharma

Legal name

ProMed Pharma, LLC

Website

https://promedpharmallc.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

ProMed Pharma is a privately held CDMO specializing in polymer-based long-acting injectable and implantable drug delivery systems, serving pharmaceutical and medical device companies from feasibility through commercial cGMP manufacturing across multiple therapeutic areas.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Contract pharmaceutical manufacturing
• Long-acting injectables
• Polymer drug delivery
• Implantable dosage forms
• Drug-device combination products

Headquarters

HQ city

Maple Grove

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: ProMed Pharma generates revenue through contract development and manufacturing services for pharmaceutical and medical device companies. Services span the full product lifecycle from early-stage formulation feasibility (10-20 projects annually) through preclinical/toxicology supplies, clinical trial material, to commercial manufacturing. The company operates on a project-based model with dedicated manufacturing suite agreements and cGMP production contracts.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

ProMed Pharma is a contract development and manufacturing organization (CDMO) that develops and manufactures polymer-based long-acting injectable and implantable dosage forms for pharmaceutical and medical device companies. The company offers end-to-end services from early-stage formulation feasibility (10–20 projects annually, 4–8 week turnaround) through tech transfer, scale-up, cGMP clinical and commercial manufacturing, device assembly/packaging/sterilization, and analytical and stability testing. Core technology platforms include silicone matrix, EVA polymer, and biodegradable PLGA microsphere drug delivery systems, with proprietary Faros™ microsphere technology and dedicated manufacturing suites for HPAPI handling.

Product overview

ProMed Pharma is a Contract Development and Manufacturing Organization (CDMO) specializing in long-acting injectable and implantable dosage forms. The company offers a comprehensive portfolio of polymer-based drug delivery services and technologies including Polymers for Controlled Release, Injection Molding, Extrusion, and Microspheres as core manufacturing capabilities. These capabilities are supported by integrated service offerings spanning Drug Product Feasibility, Tech Transfer/Scale-up, cGMP Manufacturing, Device Assembly/Packaging/Sterilization, and Analytical & Stability Testing. The company applies these technologies across key application areas including Ophthalmology, Women's Health, Oncology, Drug-Device Combination Products, and Macromolecule Delivery. Notable named technologies include the Faros™ Microsphere Technology for sustained-release formulations.

Differentiator

Problem solved

Functional benefit

Brands

• Faros™ Microsphere Technology: Proprietary microsphere technology for sustained drug release formulations

Products and services

• Drug Product Feasibility Early-stage formulation and proof-of-concept service demonstrating drug delivery approaches in 4–8 weeks for pharmaceutical and medical device companies; handles approximately 10–20 feasibility projects annually.
• Tech Transfer, Optimization & Scale-up Service transitioning programs from feasibility to production-level manufacturing, including process optimization, product sterilization definition, analytical method pre-validation, and preliminary stability testing.
• cGMP Manufacturing Full cGMP manufacturing services compliant with 21 CFR 211, including material handling, cleanroom monitoring, equipment operation, process parameters, and product release for clinical and commercial supply.
• Device Assembly, Packaging, and Sterilization Service assembling dosage forms into applicators, performing primary packaging, and managing sterilization logistics including gamma, e-beam, and ethylene oxide methods.
• Analytical & Stability Testing Comprehensive analytical testing including drug assay, impurities, content uniformity, in vitro elution testing, mechanical testing, and dimensional characterization, supported by a 2,000+ sq ft analytical laboratory equipped with HPLC, UPLC, GPC, FTIR, DSC, Karl Fischer, rheometry, viscometry, USP apparatus, laser microscopy, and tensile testing.
• Faros™ Microsphere Technology Proprietary microsphere technology platform for sustained-release drug delivery, producing tightly controlled 2–50 µm spherical non-aggregating particles with engineered release profiles from approximately 3 to over 180 days; compatible with small molecule APIs and peptides, deliverable at concentrations above 800 mg/ml through needles as small as 30G.
• Resorbable Long-Acting Contraceptive Implant (Development Program) Development program for a novel fully resorbable contraceptive implant providing 18 months of contraception and eliminating the need for clinic removal, funded by the Bill & Melinda Gates Foundation and targeted at low and middle income countries.

Quantifiable outcome

• Proof of concept demonstrated in 4-8 weeks for early-stage feasibility projects
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Four partnerships are on record, tiered core.

• Undisclosed Pharmaceutical Partner (HPAPI)coreStrategic or Co-development Partner · 1 June 2026An undisclosed pharmaceutical partner committed to a second dedicated manufacturing suite at Niagara Lane facility. The suite is specifically configured for highly potent active pharmaceutical ingredients (HPAPIs) and will support development and future commercial production of complex generic drug products. Incorporates advanced containment technologies and environmental controls for potent compound processing.
• Undisclosed Late-Stage Pharmaceutical PartnercoreStrategic or Co-development Partner · 1 January 2026An undisclosed pharmaceutical partner committed to a dedicated manufacturing suite at the new Niagara Lane facility. The partner is entering late-stage clinical trials with intent for commercial production pending approval. This represents the first of four planned manufacturing suites at Niagara Lane for ophthalmic implants and sustained-release drug delivery products.
• Bora PharmaceuticalscoreOthers · 1 August 2025ProMed Pharma acquired a 28,000 square foot pharmaceutical manufacturing facility from Bora Pharmaceuticals located at 2200 N Niagara Lane, Plymouth, Minnesota. The facility includes advanced infrastructure for GMP-compliant production with controlled warehousing, Grade C and D manufacturing space, and expansion capacity. The acquisition significantly expanded ProMed Pharma's commercial manufacturing footprint.
• SpineThera Inc.coreStrategic or Co-development Partner · 1 April 2024ProMed Pharma acquired SpineThera's cGMP manufacturing operational assets including a controlled environment manufacturing suite, process equipment, and obtained an option to license microsphere intellectual property. SpineThera retains ownership of SX600 IP and becomes a customer of ProMed for manufacturing its lead asset, dexamethasone microspheres for epidural injection. SpineThera's experienced manufacturing team joined ProMed Pharma.

Scale indicators8 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Evonik Health Care: Evonik Health Care offers polymer-based drug delivery CDMO services including PLGA, bioresorbable polymers, and contract manufacturing for complex parenteral and long-acting injectable dosage forms. Direct competitor to ProMed in polymer CDMO with overlapping capabilities in microspheres and sustained-release formulations.
• Ascendia Pharma Solutions: Ascendia Pharma Solutions is a specialty CDMO offering pre-formulation, formulation development, and cGMP manufacturing of injectables including nanoemulsions, nanosuspensions, and lyophilized products. Comparable mid-sized CDMO serving similar early- to commercial-stage injectable customers.
• Exela Pharma Sciences: Exela Pharma Sciences is a specialty CDMO focused on sterile injectable and lyophilized drug products for pharmaceutical clients. Direct competitor to ProMed in complex parenteral CDMO services with comparable mid-market positioning.
• Oakwood Labs: Oakwood Labs is a privately held specialty CDMO focused on polymer-based long-acting injectable formulations, including microspheres and biodegradable implants. Closest peer in scale and technology focus to ProMed, serving similar pharmaceutical customers with sustained-release parenteral dosage forms.
• Halo Pharma (Noble Pharma): Halo Pharma is a US-based CDMO providing oral solid, liquid, and topical dosage form development and manufacturing. Comparable mid-market CDMO serving pharmaceutical customers across development and commercial stages with overlap in specialty dosage forms.
• Tapemark: Tapemark is a privately held CDMO specializing in transdermal patches, topical, and oral dissolvable films with cGMP manufacturing capabilities. Comparable mid-sized specialty CDMO focused on complex non-oral drug delivery dosage forms serving pharmaceutical customers.

Emerging players

• SpineThera Inc. SpineThera is a clinical-stage pharmaceutical developer of sustained-release injectable therapies (SX600 dexamethasone microspheres) whose manufacturing assets were acquired by ProMed in 2024. Now operates as a customer of ProMed and an option licensor of microsphere IP, creating a tightly coupled emerging player relationship.

Broad incumbents

• Catalent (Novo Holdings): Catalent is one of the largest global CDMOs offering softgel, oral, injectable, and biologic drug delivery services, including long-acting injectable and implant capabilities. It competes with ProMed for pharmaceutical contract manufacturing customers but across a much broader portfolio and at greater scale.
• Lonza (Small Molecules CDMO): Lonza is a leading global CDMO with capabilities across small molecules, biologics, and drug product services including complex parenteral formulations. Competes with ProMed for commercial-scale sterile injectable and specialty drug product contracts at much larger scale.
• Patheon (Thermo Fisher Scientific): Patheon, part of Thermo Fisher's pharma services, is a large global CDMO offering drug substance, drug product, and packaging services including sterile injectables. It overlaps with ProMed on injectable and combination product manufacturing but serves a much broader market and customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProMed Pharma